Department of Internal Medicine. University of Arkansas for Medical Sciences; Little Rock, Arkansas, USA.
Division of Gastroenterology and Hepatology. University of Arkansas for Medical Sciences; Little Rock, Arkansas, USA.
Ann Hepatol. 2018 January-February;17(1):76-84. doi: 10.5604/01.3001.0010.7537.
Practitioners treating hepatitis C (HCV) provide healthcare to a special population with high rates of substance abuse and psychiatric disorders. We investigated the psychosocial profile in HCV patients and tested what variables affect commencement of antiviral therapy.
Recreational drug use (RDU), marijuana (THC), alcohol use, and psychiatric history were initially investigated with a questionnaire prior to history and physical. Following an educational intervention, we reinterrogated patients for RDU and THC use, and revision of initial statement was documented. Variables affecting commencement of antiviral therapy were analysed with logistic regression.
Out of 153 patients, 140 (92%) answered the questionnaire. Intervention increased total yield by 6%, however, 39% (11/28) of those initially denying use revised their statement. Drug screening identified 9 more patients with RDU/THC use. Half of patients consuming alcohol were heavy drinkers, and psychiatric disease was identified in 54%. Only 73 (48%) of 139 patients eligible for antivirals received treatment. Multivariable analysis revealed that younger patients (OR = 1.04, 95% CI 1.01-1.08), and those testing positive on drug screen (OR = 0.41, 95% CI 0.19-0.92) were less likely to be treated. Denial by insurance and loss to follow-up were the most common reasons for not starting antiviral treatment.
Substance abuse is highly prevalent among HCV patients, and it is difficult to tell prior from current users. Integral care of HCV patients should include a diligent screen for substance abuse and rehabilitation referral, aiming to increase the pool of patients eligible for antiviral therapy. This can only be achieved through a multidisciplinary approach.
治疗丙型肝炎(HCV)的医生为滥用药物和精神障碍高发的特殊人群提供医疗服务。我们调查了 HCV 患者的社会心理状况,并检验了哪些变量会影响抗病毒治疗的开始。
在进行病史和体检之前,我们通过问卷初步调查了消遣性药物使用(RDU)、大麻(THC)、酒精使用和精神病史。在进行教育干预后,我们再次询问了患者 RDU 和 THC 使用情况,并记录了最初陈述的修订情况。我们使用逻辑回归分析了影响开始抗病毒治疗的变量。
在 153 名患者中,有 140 名(92%)回答了问卷。干预措施使总应答率提高了 6%,但最初否认使用的患者中有 39%(11/28)修改了陈述。药物筛查发现了另外 9 名使用 RDU/THC 的患者。一半的饮酒患者为重度饮酒者,54%的患者患有精神疾病。在 139 名有资格接受抗病毒治疗的患者中,只有 73 名(48%)接受了治疗。多变量分析显示,年轻患者(OR = 1.04,95%CI 1.01-1.08)和药物筛查阳性的患者(OR = 0.41,95%CI 0.19-0.92)不太可能接受治疗。保险拒绝和失访是未开始抗病毒治疗的最常见原因。
HCV 患者中滥用药物的情况非常普遍,且很难判断是当前使用者还是过去使用者。HCV 患者的综合治疗应包括对药物滥用的认真筛查和康复转诊,以增加有资格接受抗病毒治疗的患者人数。这只能通过多学科方法实现。